Tourette Syndrome Treatment Market: By Medical Treatment (Psychotherapy, Behaviour, Medication [Pimozide, Haloperidol, Serotonin Reuptake Inhibitors, ADHD Drugs]) and Geography

Tourette Syndrome Treatment Market Size was valued at USD 2.60 billion in 2022 and is poised to grow at a CAGR of 4.4% from 2023-29. Tourette syndrome is one type of neurological disorder characterized by stereotypic, repetitive involuntary movements known as tics. This syndrome usually affects people of age between 2 to 15 years. Tourette syndrome is 4 times more common in males than females. The patients may experience simple ticks including eye blinking, head jerking, eye darting, or nose twitching. Complex ticks include obscene gesturing, hopping, touching or smelling objects, and stepping in a certain pattern. Companies in the global Tourette syndrome management market are actively involved in the R&D activities in the development of new treatment options to treat the syndrome.

Furthermore, collaborations and acquisitions are also the key strategies adopted by the companies to maximize their market share. For instance, Neurocrine's INGREZZA is under phase 2 clinical trials for the treatment of Tourette syndrome. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behavior and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. The Tourette Syndrome Treatment Market report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.